ERBB2 and bladder transitional cell carcinoma: To our knowledge, this is the first attempt to correlate cisplatin-resistance with ErbB3 expression and activation in the context of advanced BlCa and may affect patient selection for upcoming drugs targeting the HER2/ErbB3 axis.